Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know (2022)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1016/j.pcad.2022.01.002
- Subjects: LIPOPROTEÍNAS; TOMADA DE DECISÃO; PRÁTICA PROFISSIONAL
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2022
- Source:
- Título: Progress in cardiovascular diseases
- ISSN: 0033-0620
- Volume/Número/Paginação/Ano: v. 73, p. 32-40, 2022
- Status:
- Artigo aberto em periódico híbrido (Hybrid Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
VIRANI, Salim S et al. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in cardiovascular diseases, v. 73, p. 32-40, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.pcad.2022.01.002. Acesso em: 25 mar. 2026. -
APA
Virani, S. S., Koschinsky, M. L., Maher, L., Mehta, A., Orringer, C. E., Santos Filho, R. D. dos, et al. (2022). Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in cardiovascular diseases, 73, 32-40. doi:10.1016/j.pcad.2022.01.002 -
NLM
Virani SS, Koschinsky ML, Maher L, Mehta A, Orringer CE, Santos Filho RD dos, Shapiro MD, Saseen JJ. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know [Internet]. Progress in cardiovascular diseases. 2022 ; 73 32-40.[citado 2026 mar. 25 ] Available from: https://doi.org/10.1016/j.pcad.2022.01.002 -
Vancouver
Virani SS, Koschinsky ML, Maher L, Mehta A, Orringer CE, Santos Filho RD dos, Shapiro MD, Saseen JJ. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know [Internet]. Progress in cardiovascular diseases. 2022 ; 73 32-40.[citado 2026 mar. 25 ] Available from: https://doi.org/10.1016/j.pcad.2022.01.002 - Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- Familial hypercholesterolaemia: PCSK9 inhibitors are coming [comentário]
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
- Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
- USPSTF recommendation on screening for lipid disorders in children and adolescents. [Carta]
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity
- Relation Between Self-Reported Physical Activity Level, Fitness, and Cardiometabolic Risk
- The Role of Statins in Current Guidelines
- Evolocumab in pediatric heterozygous familial hypercholesterolemia
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
